Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations

Melanoma Res. 2020 Dec;30(6):630-631. doi: 10.1097/CMR.0000000000000676.

Authors

Norbertus A Ipenburg¹, Jos A van der Hage², Julia A Newton-Bishop³, Mark Harland³, Nicole A Kukutsch¹, Hildur Helgadottir⁴, Maarten H Vermeer¹, Omgo E Nieweg⁵, Remco van Doorn¹

Affiliations

¹ Department of Dermatology.
² Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
³ Section of Biostatistics and Epidemiology, Leeds Institute of Medical Research, Leeds, UK.
⁴ Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
⁵ Department of Surgical Oncology, Melanoma Institute Australia, Sydney, Australia.

PMID: 33156206
DOI: 10.1097/CMR.0000000000000676

No abstract available

Publication types

Letter

MeSH terms

Cyclin-Dependent Kinase Inhibitor p16 / metabolism*
Female
Germ-Line Mutation
Humans
Male
Melanoma / pathology
Melanoma / surgery*
Melanoma, Cutaneous Malignant
Sentinel Lymph Node Biopsy / methods*
Skin Neoplasms / pathology
Skin Neoplasms / surgery*

Substances

CDKN2A protein, human
Cyclin-Dependent Kinase Inhibitor p16

Grants and funding